SBIR Phase II: Novel Peritoneal Dialysis Catheter to Reduce Infections

Information

  • NSF Award
  • 1230432
Owner
  • Award Id
    1230432
  • Award Effective Date
    8/15/2012 - 12 years ago
  • Award Expiration Date
    10/31/2016 - 8 years ago
  • Award Amount
    $ 1,105,000.00
  • Award Instrument
    Standard Grant

SBIR Phase II: Novel Peritoneal Dialysis Catheter to Reduce Infections

This Small Business Innovation Research (SBIR) Phase II project is aimed at improving the quality of life of dialysis patients through the development if a new disinfection process of the peritoneal dialysis (PD) catheter connection that will reduce infections related to PD. The prevalence of PD among dyaliss patients is increasing and infection rate has become a target for critical improvement. Since PD is a self-administered treatment, patient adherence to the set-up protocol is vital to ensure that sterility is observed. Unfortunately, this is not always the case - infection remains a pressing concern. The objective of this research is to circumvent the need to for complete patient compliance, and introduce a device that will decontaminate the interfaces of PD catheters that are at most risk of contamination. Research objectives focus on enhancing the device design in an effort to achieve a multifold logarithmic bacterial reduction on multiple pathogens, including bacterial and fungal. Other objectives of this project are to optimize product design, from both performance and usability standpoints. When implemented into the clinic, the disinfection device will allow peritoneal dialysis patients to safely receive the full benefit associated with this mode of treatment. <br/><br/><br/>The broader impact/commercial potential of this project is to develop a new standard of care for all catheters suffering from catheter-related infections at ports. The total addressable market for dialysis, central venous, and peripheral venous lines is $13 Billion. Catheter-related infections still presents as a dangerous health hazard for many markets and as of yet, no disinfectant has emerged to successfully address this issue. The "No Pay" rule implemented in recent years prevents hospitals from being reimbursed from infection-related cases with catheters. The disinfection device will enable the decontamination of catheters and the prevention of luminal infections, thereby greatly reducing the risk of secondary infection. For peritoneal dialysis specifically, this technology allows for home dialysis to be a more attractive option compared to hemodialysis by adding safety, reducing patient morbidity and mortality, while permitting more patients to take advantage of the quality of life benefits that peritoneal dialysis provides.

  • Program Officer
    Jesus Soriano Molla
  • Min Amd Letter Date
    8/4/2012 - 12 years ago
  • Max Amd Letter Date
    8/28/2014 - 10 years ago
  • ARRA Amount

Institutions

  • Name
    Puracath Medical Inc.
  • City
    Mountain View
  • State
    CA
  • Country
    United States
  • Address
    201 San Antonio Cir STE 105
  • Postal Code
    940400000
  • Phone Number
    4153054134

Investigators

  • First Name
    Julia
  • Last Name
    Rasooly
  • Email Address
    julia@puracath.com
  • Start Date
    8/4/2012 12:00:00 AM

Program Element

  • Text
    STTR PHASE II
  • Code
    1591
  • Text
    SMALL BUSINESS PHASE II
  • Code
    5373

Program Reference

  • Text
    Light generation & detection
  • Text
    SBIR Phase IIB
  • Text
    SBIR Tech Enhan Partner (TECP)
  • Text
    SMALL BUSINESS PHASE II
  • Code
    5373
  • Text
    Biotechnology
  • Code
    8038